Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/223 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME12192262
PMID: | 12192262
LR: | 20051117
CED: | 20020822
DCO: | 20030128
Autoren: | Jubb RW
Titel: | Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002.
Quelle: | Current opinion in rheumatology; VOL: 14 (5); p. 597-602 /200209/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 9000851
ISSN: | 1040-8711
CO: | CORHES
Institution: | University of Birmingham, Selly Oak Hospital, UK. Ronald.jubb@uhb.nhs.uk
DT: | Journal Article; Review
RN: | 45
Schlagwörter
CT: | ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; ANTIRHEUMATIC AGENTS/administration & dosage; ANTIRHEUMATIC AGENTS/*therapeutic use; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS/adverse effects; HUMANS; HYPERTENSION/chemically induced; INJECTIONS, INTRA-ARTICULAR; ISOENZYMES/antagonists & inhibitors; MEMBRANE PROTEINS; OSTEOARTHRITIS/*drug therapy; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES
CTG: | APPLIKATION, ORALE; ALTE MENSCHEN; ALTE MENSCHEN, 80 JAHRE UND ÄLTER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; ANTIRHEUMATIKA/Verabreichung & Dosierung; ANTIRHEUMATIKA/*therapeutische Anwendung; CYCLOOXYGENASE 2; CYCLOOXYGENASE-2-INHIBITOREN; CYCLOOXYGENASEINHIBITOREN/unerwünschte Nebenwirkungen; MENSCH; HYPERTONIE/chemisch hervorgerufen; INJEKTIONEN, INTRAARTIKULÄRE; ISOENZYME/Antagonisten & Inhibitoren; MEMBRANPROTEINE; OSTEOARTHROSE/*Arzneimitteltherapie; PROSTAGLANDIN-ENDOPEROXID-SYNTHASE
TE: | Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Membrane Proteins; Cyclooxygenase 2/E.C. 1.14.99.1; PTGS2 protein, human/E.C. 1.14.99.1; Prostaglandin-Endoperoxide Synthases/E.C. 1.14.99.1
CR: | E.C. 1.14.99.1; E.C. 1.14.99.1; E.C. 1.14.99.1
AB: | There have been considerable advances in the drug treatments used to treat osteoarthritis. The development of selective cyclo-oxygenase inhibitors (COX-II) and confirmation of their efficacy and gastrointestinal safety will reduce treatment morbidity in the elderly. Guidelines for safe and appropriate use of COX-II drugs are now available. The role of anti-inflammatory drugs in precipitating cardiorenal events has been highlighted but remains to be fully evaluated. Glucosamine, diacerein, and hyaluronan may all be disease-modifying drugs for osteoarthritis but confirmatory studies are still needed.

» Volltext »
» Fenster schließen »